Brendon Neuen's Publications

About Brendon Neuen's Publications

Senior Research Fellow, Renal and Metabolic
  • Nephrologist and Director, Kidney Trials, Royal North Shore Hospital
  • Clinical Associate Professor, University of Sydney
  • Conjoint Associate Professor, UNSW Sydney
  • Ph.D. ,
  • MBBS(Hons),
  • MSc(Oxon),
  • FRACP,
  • FASN

  • Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

    Nephrology Dialysis Transplantation Date published:

  • Pilot Trials in Nephrology: Establishing a BASE for Large-Scale Randomized Trials

    Journal of the American Society of Nephrology Date published:

  • SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

    The Lancet Diabetes & Endocrinology Date published:

  • A longitudinal faculty development program: supporting a culture of teaching

    BMC Medical Education Date published:

  • Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey

    BMJ Date published:

  • Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering

    Canadian Medical Association Journal Date published:

  • Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program

    Journal of the American Society of Nephrology Date published:

  • Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease

    Annals of Internal Medicine Date published:

  • Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis

    Diabetes, Obesity and Metabolism Date published:

  • Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis

    Annals of Internal Medicine Date published:

  • Reducing cardiovascular risk in people with diabetes and kidney disease

    Medical Journal of Australia Date published:

  • Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function

    Circulation Date published:

  • Canagliflozin and cardiovascular outcomes in patients with chronic kidney disease

    Date published:

  • Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease

    Diabetes Date published:

  • The birth of @ISNeducation

    Kidney International Date published:

  • Chronic kidney disease and the global NCDs agenda

    BMJ Global Health Date published: